

Attorney Docket No. _____

DECLARATION AND POWER OF
ATTORNEY ORIGINAL PATENT APPLICATION

As a below named inventor, I hereby declare that:

Type of Application

This declaration is for the following type application:

<u> X </u>	Original
<u> </u>	Design
<u> </u>	National Stage of PCT
<u> </u>	Divisional
<u> </u>	Continuation
<u> </u>	Continuation-in-Part (CIP)

Inventorship Identification

My residence, post office address and citizenship are as stated below next to my name, I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

ELECTRIC POTENTIAL THERAPY APPARATUS AND CONTROL METHOD
OF OPTIMAL DOSE AMOUNT FOR HUMAN BODY AREA

Specification Identification

The specification of which:

 X is attached hereto.

 was filed on _____ as Application Serial No. _____
and was amended on _____
(if applicable).

 was described and claimed in PCT International Application
No. _____ filed on _____
and as amended on _____.

Acknowledgement of Review of Papers and Duty of Candor

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56, which provides:

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is canceled or withdrawn from consideration or the application becomes abandoned. Information material to the patentability of a claim that is canceled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner described by §§ 1.97 (b)–(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine; (1) prior art cited in search reports of a foreign patent office in a counterpart application, and (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

(b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and

(1) it establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or

(2) it refutes, or is inconsistent with, a position the applicant takes in:

(i) opposing an argument of unpatentability relied on by the Office, or

(ii) asserting an argument of patentability. A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

(c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:

(1) each inventor named in the application;

(2) each attorney or agent who prepares or prosecutes the application; and

(3) every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.

(d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.

_____ In compliance with this duty there is attached an information disclosure statement, 37 CFR 1.97.

I do not know and do not believe that the invention was ever known or used in the United States of America before my or our invention thereof; I do not know and do not believe that the invention was ever patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to this application; I do not know and do not believe that the invention was in public use or on sale in the United States of America more than one year prior to this application; and the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months prior to this application.

Priority Claim

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

_____ No such applications have been filed.

_____ X Such applications have been filed as follows.

Country	Application Number	Date of Filing (Month/Day/Year)	Priority Claimed	
			Yes	No
Japan	2000-404337	December 18, 2000	X	

Power of Attorney

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Edward D. Manzo, 28, 139

Send correspondence to:

Direct telephone calls to:

Edward D. Manzo, Esq.
 COOK, ALEX, McFARRON, MANZO,
 CUMMINGS & MEHLER, LTD.
 200 West Adams Street
 Suite 2850
 Chicago, Illinois 60606-5234

Edward D. Manzo, Esq.
 (312) 236-8500

Declaration

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor Akikuni HARA

Country of Citizenship Japan

Residence and

Post Office Address c/o HAKUJU INSTITUTE FOR HEALTH SCIENCE Co., Ltd.

32-17, Oyamahigashi-cho, Itabashi-ku, Tokyo JAPAN

Inventor's Signature A. Hara Date 2001/12/3

Full name of second inventor Nobuo UENAKA

Country of Citizenship Japan

Residence and

Post Office Address c/o HAKUJU INSTITUTE FOR HEALTH SCIENCE Co., Ltd

32-17, Oyamahigashi-cho, Itabashi-ku, Tokyo JAPAN

Inventor's Signature N. Uenaka Date 2001/12/3

Atty Docket

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Akikuni HARA et al

Serial No.:

Filed: Herewith

For: Electric Potential Therapy Apparatus
and Control Method of Optimal Dose
Amount for Human Body Area

To:

Commissioner for Patents
Washington D.C. 20231

)
) EL 845498548
) "Express Mail" Mailing Label No. _____
) Date of Deposit December 14, 2001
)
) I hereby certify that this correspondence is being
) deposited with the United States Postal Service
) "Express Mail Post Office to Addressee" service
) under 37 CFR 1.10 on the date indicated above
) and is addressed to: Commissioner
) for Patents, Washington, D.C. 20231
) Name. Yue X. Quan
) (typed or printed)

Signature Yue X. Quan


APPOINTMENT OF ASSOCIATE ATTORNEYS

Sir:

Please recognize the following as my associate attorneys in
the above captioned application:

Fred S. Lockwood	Reg. No. 14,772
Granger Cook, Jr.	Reg. No. 18,283
Daniel C. McEachran	Reg. No. 19,804
William H. Magidson	Reg. No. 19,902
Edward M. Keating	Reg. No. 20,646
John L. Alex	Reg. No. 22,017
Daniel M. Riess	Reg. No. 24,375
Eugene M. Cummings	Reg. No. 24,398
Raymond M. Mehler	Reg. No. 26,306
Gary W. McFarron	Reg. No. 27,357
Joel H. Bock	Reg. No. 29,045
Stephen B. Heller	Reg. No. 30,181
David Lesht	Reg. No. 30,472
Andrew G. Kolomayets	Reg. No. 33,723
Mark J. Murphy	Reg. No. 34,225
David M. Mundt	Reg. No. 41,207
Michael J. McGee	Reg. No. 43,789

Respectfully submitted,



Edward D. Manzo
Attorney of Record
Registration No. 28,139

COOK, ALEX, MCFARRON, MANZO,
CUMMINGS & MEHLER, LTD.
200 West Adams Street, Suite 2850
Chicago, Illinois 60606
(312) 236-8500